DexCom (DXCM) to Release Earnings on Thursday

DexCom (NASDAQ:DXCM) is scheduled to release its earnings data after the market closes on Thursday, October 24th. Analysts expect DexCom to post earnings of $0.44 per share for the quarter. DexCom has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the company posted $0.34 earnings per share. DexCom’s revenue was up 15.3% compared to the same quarter last year. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Stock Performance

Shares of DXCM opened at $73.08 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom has a one year low of $62.34 and a one year high of $142.00. The firm has a market capitalization of $29.06 billion, a P/E ratio of 47.15, a PEG ratio of 2.16 and a beta of 1.18. The business has a fifty day moving average of $70.03 and a 200 day moving average of $99.06.

Analysts Set New Price Targets

Several brokerages recently commented on DXCM. UBS Group cut their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Robert W. Baird boosted their price target on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. BTIG Research cut their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Wells Fargo & Company cut their price target on DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, October 12th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.73.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,824 shares of company stock worth $126,390. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.